共 115 条
[1]
Goldstraw P(2016)The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer J Thorac Oncol 11 39-51
[2]
Chansky K(2016)Lung cancer statistics Adv Exp Med Biol 893 1-19
[3]
Crowley J(2018)A review of guidelines for lung cancer J Thorac Dis 10 S1556-S1663
[4]
Torre L(2013)Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology J Thorac Oncol 8 823-859
[5]
Siegel R(2020)The great escape: tumour cell plasticity in resistance to targeted therapy Nat Rev Drug Discov 19 39-56
[6]
Jemal A(2006)Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542-2550
[7]
Bironzo P(2014)Programmed death-1 pathway in cancer and autoimmunity Clin Immunol 153 145-152
[8]
Di M(2017)First-line Nivolumab in stage IV or recurrent non–small-cell lung cancer N Engl J Med 376 2415-2426
[9]
Lindeman NI(2018)Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer N Engl J Med 379 2040-2051
[10]
Boumahdi S(2018)Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 378 2078-2092